| Company Name: |
Suzhou Meishi Biotechnology Co., Ltd.
|
| Tel: |
1173954148q |
| Email: |
meishipharma@126.com |
| Products Intro: |
Product Name:178600-20-9 CAS:178600-20-9 Purity:99% HPLC Package:1G;5G;10G;100G;1KG;
|
| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:ALRT 1550 CAS:178600-20-9 Purity:98%+ HPLC Package:10mg,500mg,1g,2g,5g,10g,More
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:ALRT 1550 CAS:178600-20-9 Package:25mg/RMB 10600;100mg/RMB 17500;50mg/RMB 13800
|
2,4,6-Octatrienoicacid, 7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-, (2E,4E,6E)- manufacturers
- ALRT 1550
-
- $1520.00
-
2026-05-11
- CAS:178600-20-9
- Purity:
- Supply Ability: 10g
|
| | 2,4,6-Octatrienoicacid, 7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-, (2E,4E,6E)- Basic information |
| Product Name: | 2,4,6-Octatrienoicacid, 7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-, (2E,4E,6E)- | | Synonyms: | 2,4,6-Octatrienoicacid, 7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-, (2E,4E,6E)-;ALRT 1550;ALRT1550;ALRT-1550;ALRT-550;LG1550;LG-1550;LGD-1550 | | CAS: | 178600-20-9 | | MF: | C23H32O2 | | MW: | 340.49898 | | EINECS: | | | Product Categories: | | | Mol File: | 178600-20-9.mol | ![2,4,6-Octatrienoicacid, 7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-, (2E,4E,6E)- Structure](CAS/20180527/GIF/178600-20-9.gif) |
| | 2,4,6-Octatrienoicacid, 7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-, (2E,4E,6E)- Chemical Properties |
| | 2,4,6-Octatrienoicacid, 7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-, (2E,4E,6E)- Usage And Synthesis |
| Uses | ALRT1550 (LGD1550) is a selective retinoic acid receptor (RAR) agonist that binds RARs with exceptional potency, with Kd values of approximately 1-4 nM. ALRT1550 exhibits anti-proliferative activity, with an IC50 value of 0.22 nM in UMSCC-22B squamous carcinoma cells. In a mouse tumor xenograft model, ALRT1550 inhibited tumor growth in a dose-dependent manner, achieving a maximum inhibition rate of 89%. ALRT1550 is applicable for research in the field of cancer[1][2]. | | References | [1] Shalinsky DR, et al. A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice. Cancer Res. 1997 Jan 1;57(1):162-8. PMID:8988059 [2] Zhang L, et al. Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells. J Med Chem. 1996 Jul 5;39(14):2659-63. DOI:10.1021/jm960285j |
| | 2,4,6-Octatrienoicacid, 7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-, (2E,4E,6E)- Preparation Products And Raw materials |
|